RT Journal Article
SR Electronic
T1 Efficacy of N-163 beta-glucan in beneficially improving biomarkers of relevance to muscle function in patients with muscular dystrophies in a pilot clinical study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.20.23292982
DO 10.1101/2023.07.20.23292982
A1 Raghavan, Kadalraja
A1 Sivakumar, Thanasekar
A1 Ichiyama, Koji
A1 Yamamoto, Naoki
A1 Balamurugan, Mangaleswaran
A1 Dedeepiya, Vidyasagar Devaprasad
A1 Senthilkumar, Rajappa
A1 Preethy, Senthilkumar
A1 Abraham, Samuel JK
YR 2023
UL http://medrxiv.org/content/early/2023/07/24/2023.07.20.23292982.abstract
AB Background: Muscular dystrophies other than Duchenne muscular dystrophy (DMD) are genetic diseases characterized by increasing muscle weakness, loss of ambulation, and ultimately cardiac and respiratory failure. There are currently no effective therapeutics available. Having demonstrated the efficacy of a N-163 strain of Aureobasidium Pullulans (Neu-REFIX) produced B-1, 3-1,6-Glucan in pre-clinical and clinical studies of Duchenne muscular dystrophy (DMD) earlier, we assessed the effectiveness of this novel Beta glucan in the other muscular dystrophies in the present study.Methods: In this 60-day study, six patients with muscular dystrophies other than DMD consumed one 8g gel of Neu-REFIX beta-glucan along with their usual standard of care treatment regimen, and their biomarkers of relevance to muscle function such as serum calcium (SC), creatinine phosphokinase (CPK), and alkaline phosphatase (ALP) levels along with functional improvement criteria, viz., Medical research council (MRC) scale and North Star Ambulatory assessment (NSAA) were assessed at baseline and following the intervention.Results: After the intervention, the SC levels significantly decreased from a mean baseline value of 9.28 mg/dL to 8.31 mg/dL (p-value = 0.02). With a p-value of 0.29, the mean CPK value dropped from 2192.33 IU/L to 1567.5 IU/L. Following the intervention, the ALP levels dropped from 200.33 to 75.5 U/L (p-value =0.15). MRC scale improved in three out of six patients. NSAA remained stable. There were no adverse effects.Conclusion: This study has proven the safety of Neu REFIX beta-glucan food supplement and its efficacy in improving both plasma biomarkers and functional parameters of muscle in a short duration of 2 months. Further validation by evaluation of muscle function for a longer duration is recommended to confirm the efficacy of Neu-REFIX food supplement as a potential adjuvant DMT in muscular dystrophies.Competing Interest StatementAuthor Samuel Abraham is a shareholder in GN Corporation, Japan which holds shares of Sophy Inc., Japan., the manufacturers of novel beta glucans using different strains of Aureobasidium pullulans; a board member in both the companies and also an applicant to several patents of relevance to these beta glucans.Clinical TrialThe study was registered in Clinical trials registry of India, CTRI/2022/05/042917Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was registered in Clinical trials registry of India, CTRI/2022/05/042917 and approved by the ethics committee of Saravana Multispeciality Hospital-Institutional Ethics Committee, IndiaI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript